Overview of Transdermal Drug Delivery System

International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 6 Issue 4, May-June 2022 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470
@ IJTSRD | Unique Paper ID – IJTSRD50107 | Volume – 6 | Issue – 4 | May-June 2022 Page 670
Overview of Transdermal Drug Delivery System
Sayali Dhepe*, Manisha Sukre, Vikram Veer
P.D.E.A.'s Shankarrao Ursal College of Pharmaceutical Sciences and Research Centre,
Kharadi, Pune, Maharashtra, India
ABSTRACT
Transdermal drug delivery systems are topically administered
medicaments. Transdermal drug transport structures (TDDS) are the
dosage shape of adhesive patch this is positioned on the skin to
deliver specific dose of medication through the skin and in to the
blood stream. The main objective of transdermal drug delivery
system is to deliver drug into systemic circulation through skin at
predetermined rate with minimal inter and intrapatients variation.
This article gives a brief overview over principles behind transdermal
drug delivery, as well as the advantages and disadvantages of
transdermal therapeutic system and the recent innovations inthe field
of transdermal drug delivery and also describe the methods of
preparation of different types of transdermal patches, evaluation
parameters and some available marketed products.
KEYWORDS: Epidermis, Transdermal drug delivery system, skin
*Corresponding Author: Sayali Dhepe
How to cite this paper: Sayali Dhepe |
Manisha Sukre | Vikram Veer
"Overview of Transdermal Drug
Delivery System"
Published in
InternationalJournal
of Trend in
Scientific Research
and Development
(ijtsrd), ISSN: 2456-
6470, Volume-6 |
Issue-4, June 2022, pp.670-682, URL:
www.ijtsrd.com/papers/ijtsrd50107.pdf
Copyright © 2022 by author(s) and
International Journal of Trend in
Scientific Research and Development
Journal. This is an
Open Access article
distributed under the
terms of the Creative Commons
Attribution License (CC BY 4.0)
(http://creativecommons.org/licenses/by/4.0)
INTRODUCTION
The first transdermal system, transdermal Scop
(Baxter), was approved by Food and Drug
administration in 1979 for the prevention of nausea
and vomiting associated with travel, particularly at
sea. Transdermal drug transport gadget includes all
topically administered drug formulations intended to
deliver the active ingredients into the circulation.
Transdermal delivery provides a leading edge over
injectable and oral routes by increasing patients’
compliance and avoiding first pass metabolism. The
transdermal drug delivery system (TDDS),
Commonly Known as “patches” is a dosage formthat
is designed to distribute a therapeutically effective
amount of drug over the skin of a patient.
Transdermal delivery provides a leading edge over
injectable and oral routes by increasing Patients
compliance avoiding first pass metabolism. The
transdermal drug delivery system (TDDS), know as
patches, is a dosage from that is designed to distribute
a therapeutically effective amount of drug over the
skin of a patient. Transdermal drug shipping is the
non-invasive transport of medicines from the floor of
medications from the surface of skin. Transdermal
drug delivery system (TDDS) are dosage forms
designed to deliver a therapeutically effective dose of
drug across a patient’s skin.
 DEFINATION: - Transdermal drug shipping
systems are topically administered medicaments
inside the shape of patch that deliver drugs for
systemic effects at a predetermined and controlled
rate.
 ADVANTAGES OF TRANSDERMAL DRUG
DELIVERY SYSTEM: -
1. First pass metabolism of drug get avoided.
2. Transdermal medication delivers a steady
infusion of the drug over prolonged period of
time, therefore avoiding side effects and
therapeutic failure frequently associated with
intermittent dosing can also be avoided.
3. Reducing the typical dosing schedule to once
daily.
4. Avoiding of gastrointestinal incompatibility.
5. Ability to deliver the drug more selectively to a
specific site.
6. It can be used as an alternate to oral drug delivery
system for those patients, who find difficulty in
taking drugs through oral route.
IJTSRD50107

International Journal of Trend in Scientific Research and Development @ www.ijtsrd.com eISSN: 2456-6470
7. Self-administration can be done.
8. Transdermal drug delivery enables the avoidance
of gastrointestinal absorption with its associated
pitfalls of enzymatic and pH associated
deactivation.
9. Provide utilization of drug with short biological
half-lives, narrow therapeutic window.
10. This method avoids direct effect on stomach and
intestine.
11. Continuity of drug administration permitting the
use of the drug with short biological half-life.
12. Number of doses get reduces which improves
patient compliance.
13. Predictable and extended duration of activity.
14. Enhance therapeutic efficacy.
15. Offers long duration of action.
16. System changes of allergic reaction at the site of
application like itching, rashes, local edema etc.
 DISADVANTAGES OF TRANSDERMAL
DRUG DELIVERY SYSTEM:
1. Many drugs with a hydrophilic structurepermeate
the skin too slowly to be therapeutic benefit.
2. Drug with hydrophilic character is less suitable
with lipophilic character because of low
permeability.
3. Drug having affinity for both lipophilic and
hydrophilic phases.
4. Long time adhere is difficult.
5. Only relatively potent drugs are suitable
candidates for TDDS because natural limit of
drug entry imposed by skin impermeability.
 Anatomy of the Skin: -
Transdermal drug act through the largest organ of the
body i.e., Skin.
Skin structure: - The pores and skin’s number one role is to defend the body from germs, ultraviolet (UV)
radiation, chemical compounds, allergies, and water loss by acting as a barrier between the bodyand the external
environment. With a surface area of 1.7 m2, skin is the most accessible and largest organ ofthe body, accounting
for 16 percent of an average person's total body mass.
Figure: Structure of Skin
The three main regions of the skin are
1. The dermis, which incorporates the stratum corneum, is the outermost layer of the skin.
2. The epidermis, the middle layer, and
3. The hypodermis is innermost layer of the skin
Epidermis: - The epidermis
 The viable epidermis
 A non-viable epidermis (Stratum corneum)
 The stratum corneum is the epidermis' maximum superficial layer. The dermis is stratified squamous
epithelium. The main cells of the dermis are the keratinocytes, which synthesis the protein keratin. Protein
bridges known as desmosomes connect the keratinocytes, that are in a regular kingdomoftransition fromthe
deeper layers to the superficial.
 The multi-layered epidermis varies in thickness, depending on cell size and number of cell layers of
epidermis, ranging from 0.8 mm on palms and soles down to 0.06 mm on the eyelids.

 The epidermis varies in with water-retaining keratin proteins. The mobile form and orientationofthe keratin
proteins upload power to the stratum corneum.
 The movement of epidermal cells to this generally takes approximately 28 days and is known as the
epidermal transit time.
 Dermis: -
 Dermis is the layer of skin simpy underneath the epidermis that is 3 to 5 nm thick layer and is composed ofa
matrix of connective tissues, which contains blood vessels, lymph vessels and nerves. The cutaneous blood
supply has important feature in regulation of body temperature. It also offers vitamins and oxygen to the
pores and skin while removing pollution and waste merchandise.
 The dermis is round 2–3 mm thick and is made of collagenous (70%) and elastin fibers, which offer the skin
energy and versatility.
 The dermis includes blood arteries that supply nutrients to both the epidermis and the dermis.
Two layers comprise the dermis: -
 A thin papillary layer
 A thicker reticular layer.

 Hypodermis: -
 The hypodermis, additionally known as the subcutaneous layer, is the pores and skin's lowest layer and is
made up of a network of fat cells. It's miles the layer that connects the skin to the frame's underlying tissues,
inclusive of muscle groups and bone. It carries most important blood vessels and nerves to pores and skin
and may include sensory pressure organs.
 The hypodermis layer consists of free connective tissues and its, thickness varies according to the surface of
body. As a result, the hypodermis' main roles are physical shock protection, heat insulation, and support and
conductance of the skin's vascular and neurological signals.
 For transdermal drug delivery, drug has to penetrate via most of these 3 layers and attain into systemic
circulation while in case of topical drug delivery only penetration through stratum corneum is critical after
which retention of drug in skin layers is favored.
 Components of TDDS: -
Transdermal drug delivery system basic components: -
1. The drug.
2. Polymer matrix.
3. Permeation enhancers.
4. Adhesive.
5. Backing layer.
6. Release linear.
1. Drug:
Drug that may be administered via transdermal drug shipping machine are decided on after considering the
different properties of the drug that includes physiological, chemical, and biological along with the
Pharmacodynamics and pharmacokinetic property. Moreover, the 1/2-lifestyles, destructive effect oftransdermal
drug transport device with other course such as oral or I.V. dose is also taken into consideration at some point of
the choice of medicine for transdermal drug delivery system.
A. Physicochemical Properties: Under physicochemical properties following properties are expected from an
ideal drug for transdermal drug delivery system.
 The drug that has to be delivered through TDDS should have a molecular weight less than 1000 Daltons.
 The drug should be having similar kind of affinity towards both the phases whether it is lipophilic or
hydrophilic.
 Drug need to be having a pH that does not reason undesirable harm to the skin so the pH in the range of 4.2
TO 5.6
 Melting point of the drug ought to be low.
B. Biological Properties:
 Efficiency of drug must be such that in a dose of few mg/day it could exert the therapeutic effect.
 Drug need to have a quick half-life.

 As the drug is to be administered thru the skin then it need to be non-allergic to the recipient.
 The maximum suitable drug for which TDDS can be used is the drugs with high first bypass metabolism.
Types of Polymers used in TDDS
Sr.
No
Name of Polymers
Type of
polymer
Function
1 Gelatine, Na-alginate, natural Rubber, Gum tragacanth Natural Base and Adhesive
2 Carmellose, Methyl and ethyl cellulose Hydroxyl propyl cellulose
Semi
synthetic
Base, adhesive
3 Styrene-butadiene rubber Silicone rubber
Synthetic
elastomers
Base with adhesive
4
Polyvinyl alcohol polyethylene Polyhydroxyethyl methacrylate
(PHMA)
Synthetic
polymer
Base, adhesive
Linear, backing
Ideal polymer should be having the following properties:
 It ought to now not react with the drug that it contains.
 It ought to no longer be having any effect of its personal.
 It have to be strong enough that it does not get decomposed for the duration of storage or till the existence
span of the drug embedded in it.
 It should not be reactive to skin.
 It need to permit the diffusion of drug at desired price.
2. Penetration enhancer: - Permeation enhancer are described as substance whichare successfulofpromoting
penetration of drugs into skin and transdermal therapeutic systems offers a more reliable mean of
administering drug through the skin.
Properties of penetration enhancers: -
1. They ought to be pharmacologically inactive within the body. In other words, it shouldn’t bind to
receptor sites.
2. It have to be reliable, irritant-unfastened, and hypersensitivity-unfastened.
3. The onset of impact ought to be short, and the period of pastime need to be predictable and appropriate for
the drug being taken.
4. When the enhancer is eliminated, the attractive layer have to fast and absolutely regain its barrier properties.
5. While the barrier traits of the skin are eliminated, they should restore quickly and completely.
6. All medications and adjuvants to be formulated in topical treatments and devices should be chemically
and physically compatible with the accelerant.
7. It should be a suitable solvent for drugs if it is liquid and will be utilised in large volume fractions.
8. It should spread evenly on the skin and have a pleasing “feel” thereto.
9. It should be easy to make dermatological preparations, transdermal devices, and skin adhesives from it.

Advantages and Disadvantages of penetration enhancers: -
Advantages
1. Using penetration enhancers, increase the drug's penetration fee to a level that is sufficient for therapeutic
efficacy.
2. It’s far beneficial for facilitating the absorption of non absorbable medicine through the pores and skin .
3. It may sell transdermal absorption of topical coaching.
4. Terpenes in propylene glycol solution ,consisting of limonene, are precise penetration enhancers for
cytotoxic capsules.
5. It also serves as a charge limiter.
Disadvantages :-
1. The effective attention of a drug differs from one drug to the next.
2. Using diverse penetration enhancers in various concentrations is entirely prohibited.
3. The physicochemical houses of enhancers have a power at the body’s aspect consequences.
Types of penetration enhancers: -
1. Chemical enhancers: -
Mechanism of action: -
They act with the aid of three mechanisms
1. With the aid of disrupting the stratum corneum's lipid shape, which is pretty organised.
2. By interplay with intercellular protein.
3. Through progressed drug or solvent partitioning into the stratum corneum.
Examples:
1. Sulphoxides and similar chemicals-dimethyl sulphoxide (DMSO), dimethyl formamide (DMF), dimethyl
acetamide (DMAC)
2. Azones
3. Pyrrolidones
2. Drug vehicle based: -
Mechanism
Interaction of enhancers with the stratum corneum and the development of a SAR for enhancers with the best
properties and the least toxicity.
Example
Ion pairs and complicated coacervates chemical capability adjustment.
3. Natural penetration enhancers
Mechanism Mechanism for Terpenes it may boom one or more of following results
1. Partition coefficient
2. Diffusion coefficient
3. Lipid Extraction
4. Drug Solubility
5. Macroscopic Barrier Perturbation
6. Molecular Orientation of Terpenes Molecule with Lipid Bilayer.

Example
1. Terpens-Menthol, Linalool, Limonene, Carvacrol.
2. Crucial oil-Basil oil, Neem oil, Eucalyptus, Chenopodium, Ylang- Ylang.
4. Adhesives: -
All transdermal devices are attached to the skin with a pressure sensitive adhesive that can be placed on the
device's face or in the rear and extends peripherally. Both adhesive systems must meet the following
requirements:
1. It should aggressively attach to the skin and be easily removed.
2. Shouldn't go away a sticky residue at the pores and skin that can't be washed off.
3. Skin need to not be irritated or sensitised, as an example, Silicones, and polyisobutylene.
5. Backing membrane: -
Backing membranes are flexible and offer a good binding to the drug reservoir, as well as preventing the drug
from escaping through the top of the dosage form and allowing printing.
For example, Metallic plastic, is an impermeable substance that protects the product while it is being used onthe
skin. as an example, cellulose derivatives and polypropylene silicon.
Linear: During storage, keep the patch safe. Before using, the linear is removed.
 Types of TDDS:
1. Single-layer Drug-in-Adhesive
2. Multi-layer Drug-in-Adhesive
3. Reservoir
4. Micro reservoir system
 Single-layer Drug-in- Adhesive: On this kind the adhesive layer contains the drug. The adhesive layer not
handiest serves to adhere the various layers collectively and additionally liable for the freeing the drugtothe
pores and pores and skin. The adhesive layer is surrounded by means of a transient liner and a backing.
Fig Single layer drug-in-adhesive
 Multi-layer Drug-in-adhesive: This type is likewise similar to the unmarried layer however it consists ofa
on the spot drug launch layer and other layer could be a managed launch along side the adhesive layer. The
adhesive layer is responsible for the releasing of the drug. This patch additionally has a brief liner-layer and
a everlasting backing.

Fig. Multi-layer drug-in-adhesive.
 Reservoir system: In this gadget the drug reservoir is embedded between an impervious backing layer and a
fee controlling membrane. The drug releases simplest via the rate controlling membrane, which may be
micro porous or non-porous. within the drug reservoir compartment, the drug can be in the shape of a
solution, suspension, gel or dispersed in a solid polymer matrix. Hypoallergenic adhesive polymer may be
carried out as outer floor polymeric membrane that is well matched with drug.
Fig. Reservoir system
 Micro reservoir system: In this type the drug delivery machine is a mixture of reservoir and matrix-
dispersion gadget. The drug reservoir is formed by using first suspending the drug in an aqueous solution of
water-soluble polymer and then dispersing the solution homogeneously in a lipophilic polymer to form
thousands of unreachable, microscopic spheres of drug reservoirs. This thermodynamically volatile
dispersion is stabilized quick by means of right now pass-linking the polymer in situ through the usage of
pass linking marketers.
Fig. Matrix system
 Evaluation of TDDS:
The transdermal patches can be characterized in terms of following parameters:
 Physicochemical evaluation
 In vitro evaluation
 In vivo evaluation
Physicochemical evaluation:
TDDS can be physio-chemically evaluated in terms of these parameters:
1. Thickness: The thickness of transdermal film is determined by travelling microscope, dial gauge, screw
gauge or micro meter at different points of the film.

2. Uniformity of weight: Weight variation is studied by individually weighing 10 randomly selected patches
and calculating the average weight. The individual weight have to not deviate notably from the common
weight.
3. Drug content determination: An as it should be weighed portion of movie (approximately 100mg) is
dissolved in 100 mL of suitable solvent wherein drug is soluble after which is soluble and thenthe solutionis
shaken continuously for 24 hrs in shaker incubator. Then the whole solution is sonicated. After sonication
and subsequent filtration, drug in solution is anticipated spectrophotometrically by means of suitable
dilution. Concentration of drug is calculated by using standard graph.
4. Folding endurance: - A strip of a specified area must be cut uniformly and folded repeatedly at the same
place until it breaks. The value of the folding endurance was determined by the number of times the film
could be folded in the same place without breaking.
5. Percentage moisture content: - The prepared films are to be weighed individually and to be kept in a
desiccator containing fused calcium chloride at room temperature for 24 hours. After 24 hourthe films areto
be reweighed and decide the share moisture content material from the beneath stated formula:
Percentage moisture content = [initial weight- final weight/ final weight] × 100.
6. Tensile strength: - To determine tensile strength, polymeric films are sandwiched separately by corked
linear iron plates.
The tensile power can be calculated the use of the subsequent equation.
Tensile strength= F/a. b (1+L/l)
In which, F is the pressure required to break; a is width of movie; b is thickness of film; L is period of
movie; l is elongation of movie at destroy point.
7. Flatness: A transdermal patch should possess a smooth surface and should not constrict with time. This
could be tested with flatness examine.
% Constriction = (I1 – I2) X 100
Where, I2 = Final length of each strip and
I1 = Initial length of each strip
 IN VITRO RELEASE STUDIES:
Drug launch mechanisms and kinetics are traits of the dosage forms which play an important position in
describing the drug dissolution profile from a managed launch dosage paperwork and hence their in vivo
performance. A number of mathematical models have been developed to describe the drug dissolution kinetics
from controlled release drug delivery system.
There are various methods available for willpower of drug release fee of TDDS.
 The Paddle over Disc: (USP apparatus 5/ PhEur 2.9.4.1) This method is identical to the USP paddle
dissolution apparatus, except that the transdermal system is attached to a disc or cell resting at the bottom of
the vessel which contains medium at 32 ±5°C
 The Cylinder changed USP Basket: (USP apparatus 6 / PhEur 2.nine.4.three) this technique is just like the
USP basket type dissolution apparatus, except that the gadget is connected to the surface of a hollow
cylinder immersed in medium at 32 ±5°C The amount of drug available for absorption to the systemic pool
is greatly dependent on drug released from the polymeric transdermal movies. The drug reached at skin
surface is then handed to the dermal microcirculation with the aid of penetration through cells of dermis,
among the cells of dermis thru pores and skin appendages. practise of skin for permeation research: Hairless
animal skin and human cadaver skin are used for permeation studies. Human cadaver pores and skincanbe a
logical preference as the pores and skin version because the very last product might be used in humans. but it
isn't always easily available. So, hairless animal skin is usually preferred as it's miles effortlessly received
from animals of particular age group or intercourse.
 In vivo studies:
Transdermal patches may be in vivo evaluated in phrases of in vivo evaluations are the true depictionofthe drug
performance. The variables which cannot be taken into account during in vitro studies can be completely
explored during in vivo studies. In vivo assessment of TDDS may be performed the usage of animal fashions
human volunteers.

Animal models: Great time and resources are required to perform human research, so animal research are
desired at small scale. The most not unusual animal species used for comparing transdermaldrug deliverydevice
are mouse, hairless rat, hairless dog, hairless rhesus monkey, rabbit, guinea pig and many others. numerous
experiments conducted leads to a conclusion that hairless animals are preferred over furry animals in both in
vitro and in vivo experiments. Rhesus monkey is one of the most dependable models for in vivo assessment of
transdermal drug transport in man.
Human model: The final level of the improvement of a transdermal device involves series of pharmacokinetic
and pharmacodynamics information following software of the patch to human volunteers. Clinical trials had
been carried out to assess the efficacy, risk worried, side outcomes, patients compliances and many others.
Segment-I medical trials are carried out to determine specially protection in volunteers and segment II scientific
trials decide quick time period safety and mainly effectiveness in patients. Segment III trials indicates the safety
and effectiveness in big wide variety of affected person population and segment –IV trials at publish advertising
surveillance are executed for marketed patches to discover destructive drug reactions. Although human studies
require giants resources exceptional to assess the performance of the drug.
 New Approaches in TDDS:
1. Iontophoresis: It includes utility of contemporary (few mill-amperes) to the drug reservoir with equal
charged electrode. there is possibility of increasing the stratum corneum permeability in the presence of an
electric modern-day. Pilocarpin delivery may be taken for instance to set off sweat inside the diagnostic of
cystic fibrosis and Iontophoretic delivery of idocaine is considered as speedy method for anaesthesia.
2. Reverse Iontophoresis: Symmetrical nature of
iontophoresis (that transports ions throughout the
the skin in both directions of the membrane) has
led to its application as a non-invasive method of
extracting endogenous substances known as
REVERSE IONTOPHORESIS (RI). It's miles

considered as capacity device for therapeutic
tracking. Additionally advised for non-invasive
monitoring of Phenylketonuria by way of food
and Drug administration in 2001.
3. Photomechanical Waves: Photomechanical
waves significantly led to the stratum cornea
highly permeable to drug substance through a
possible permeabilization mechanism due to
development of transient channels.
4. Electroporation: The electric pulses are taken
into consideration to form small pores within the
stratum corneum, through which transportationof
drug occurs. For the sake of safe and painless
administration, the electrical pulses introduced by
closely spaced electrodes to reserve the electric
field within the stratum corneum.
 Patentability on TDDS: -
Transdermal drug transport representsone ofthe most
hastily advancing areas of novel drug shipping. even
though the concept of transdermal drug transport has
been acknowledged considering the fact that 1924, it
took till 1979, as FDA accredited the transdermal
delivery of scopolamine, that transdermal delivery
structures [TDDS] received huge interest as novel
tool for managed release. these drug shipping
structures are designed for managed launch of drug
via the skin into systemic move preserving constant
efficacy and decreasing dose of the drug and its
associated aspect effects. extra than two hundred
patents were granted by using the United nation
patent by myself, of which greater than 35 TDD
products have now been accepted for sale within the
US, and approximately sixteen lively elements had
been accredited for use globally. information monitor
a marketplace of $ 12.7 billion inside the yr 2005
that's predicted to increase with the aid of $ 21.5
billion within the 12 months 2010 and $ 31.five
billion inside the 12 months 2015. nearly all mainand
minor pharmaceutical agencies are developing TDDS.
There isn't always a single assessment article which
describes patents on exceptional kinds of TDDS. as a
consequence, this evaluation is designed for patents at
the extraordinary type of TDDS which would be
helpful for the researcher inside the field of TDDS.
 Future prospective of TDDS: -
The market for transdermal gadgets has been
expected at U.S. $2 billion (Barry 2001) and this
discern represents 10% of the general U.S. $28billion
drug shipping market. Such figures are surprising
while we consider that the first transdermal patch
changed into granted a licence by using the FDA in
1979, and simplest an extra nine capsules were
accredited considering the fact that that time. This
quick list of “deliverables” highlights the
physicochemical regulations imposed on pores and
skin shipping. Transdermal drug shipping has
experienced a healthful annual growth rate of 25%,
which outpaces oral drug delivery (2%) and the
inhalation marketplace (20%) (Grosh 2000). This
discern without a doubt DERMAL AND
TRANSDERMAL delivery structures 185 will
upward thrust inside the destiny as novel devices
emerge and the listing of marketed transdermal
tablets increases. The emergence of such gadgets will
increase the use of the pores and skin as a route of
management for the remedy of a variety of situations.
however, subjective and objective analysis of these
gadgets is required to make certain clinical,
regulatory, and consumer desires are met. The
devices in development are more steeply-priced and
complicated as compared with traditionaltransdermal
patch treatment plans. As such they will incorporate
electric and mechanical components that would
growth the ability protection risks to patients due to
poor operator method or device malfunction.
similarly, outcomes of the device at the skin need to
be reversible, since any permanent harm to the
stratum corneum effects within the lack of its barrier
residences and as a result its function as a protecting
organ. Regulatory our bodies additionallywillrequire
records to verify the safety of the device at the pores
and skin for both quick- or long-term use. as a result,
for any of these novel drug shipping technologies to
be successful and compete with the ones already on
the market, their safety, efficacy, portability, person-
friendliness, cost-effectiveness, and potential market
need to be addressed. The improvement of
transdermal delivery systems involves balancing
elevated transdermal delivery with affected person
safety/comfort and value. due to the fact intact skin is
not sufficiently permeable to the big majority of
medicine, enhancement methods are wished. in spite
of good sized studies for the duration of the past few
many years, chemical enhancers have performed only
limited achievement in growing transdermal shipping
of small molecules and feature simplest a especially
negative capacity to boom macromolecular delivery
underneath situations likely to be clinically desirable.
methods regarding ultrasound and electric powered
fields, which include iontophoresis and
electroporation, have more significantly elevated
transdermal delivery for small tablets and
macromolecules. The ability of those technologies to
deliver drugs efficaciously is in part counterbalanced
by using their reliance on electronically controlled
gadgets that require an energy supply, which
constrains programs and price. techniques that pierce
micron-scale holes in pores and skin, including
microneedles, thermal poration and jet injection, can

dramatically increase transdermal shipping of small
tablets, macromolecules or even particles, but more
paintings is wanted to set up safety/pores and skin
harm and price effectiveness. every of those
technologies is probably to in shape the wishes of
different applications and, in a few instances,
mixtures of enhancers might be the simplest strategy.
Given the development being made on novel
enhancement strategies, it appears that evidently
transdermal drug transport has handiest scratched the
surface of viable clinical impact. The defining feature
of transdermal delivery that motivates the
improvement of enhancement strategies is that the
drug reservoir stays outside the frame, whichpresents
a number of possibilities. as an example, a patient or
healthcare company has clean access to a transdermal
device that may be adjusted to modulate transport
thru the right interface. by means of comparison, it's
miles tough to regulate drug-launch kinetics after
management by using other routes, inclusive of the
gastrointestinal tract, the lungs or in the body. An
outside transdermal tool also has fewer cost and
substances boundaries as compared with some other
approaches. Degradation and excretion of device
substances are not applicable, and high priced
electronics or different features may be designed into
a re-usable transdermal gadget. For these reasons,
transdermal transport arguably gives the greatest
facility for managed launch of drugs. Overcoming the
roadblock of low pores and skin permeability the use
of the processes described in this assessment could be
the vital improve that shall we transdermal delivery
recognize its tremendous promise.
Conclusion: -
In recent times, the TDDS turning into a most broadly
used routes of drug management directly into
bloodstream without any pain and without rupturing
skin membrane. This article gives valuable
information about the overview of transdermal drug
delivery system its advantages, disadvantages,
Anatomy and physiology of skin, components of
TDDS, types of TDDS, Evaluation of TDDS, new
approaches in transdermal drug delivery system.
 References: -
[1] Audumbar D.M, Ritesh B, and Manojkumar P.
An updated review on transdermal drug
delivery systems. International Journal of
Advances in Scientific Research 2015; 1(06):
244-254.
[2] Himanshi T, and Ruchika S. TRANSDERMAL
DRUG DELIVERY SYSTEM: A REVIEW.
International Journal of Advances in Scientific
Research 2016; Vol. 7(6): 2274-2290.
[3] Sajid A, Maryam S, Nabeel S. The Structure of
Skin and Transdermal Drug Delivery System-
A Review. Research J. Pharm. and Tech.8 (2):
February 2015 ,103-109.
[4] Siddhant S, Santosh W and Hemant K. A
REVIEW: TRANSDERMAL DRUG
DELIVERY SYSTEM. World Journal of
Pharmaceutical Research, Volume 10, Issue 10,
381-402.
[5] Menon G.K. New Insights into Skin Structure:
Scratching the Surface. Adv. Drug Delivery.
Rev, 2002; 54: S3–S17. doi: 10.1016/S0169-
409X(02)00121-7.
[6] Chein Y.W. Transdermal drug delivery and
delivery system. In, Novel drug delivery
system, Marcel Dekker, Inc., New york, 1992;
50: 301-381.
[7] Srivastava S, Maurya A, Gupta P. A review
article on transdermal drug delivery system.
World J Pharm Pharm Sci, 2016; 5: 1702-25.
[8] Tyagi S, Goyal K. Transdermal drug delivery
system: Quality approaches and evaluation.
Innov Int J Med Pharm Sci, 2017; 2: 15-21.
[9] Sharma N, Agarwal G, Rana A, Bhat ZA,
Kumar D. A review: Transdermal drug delivery
system: A tool for novel drug delivery system.
Int J Drug Dev Res, 2011; 3: 70-84
[10] Prabhakar V, Shivendra A, Ritika S, Sharma S.
Transdermal drug delivery system: review. Int
Rese J Pharm, 2012; 3(5): 50-53.
[11] Willams A.C and barry B. W., “Penetration
Enhancers,” Adv. Drug Del. Rev, 2004; 56:
603-618.
[12] Shingade GM, Aamer Q, Sabale PM,
Gramprohit ND, Gadhave MV, Jadhv SL,
Gaikwad DD, Review on: recent trend on
transdermal drug delivery system, Journal of
Drug Delivery & Therapeutics. 2012; 2 (1), 66-
75.
[13] Patel D, Sunita A, Parmar B, Bhura N,
Transdermal Drug Delivery System: AReview,
the Pharma Innovation. 2012; 1(4), 66-75.
[14] Sharma N, Agarwal G, Rana AC, Ali Bha Z,
Kumar D, A Review: Transdermal Drug
Delivery System: A Tool For Novel Drug
Delivery System, International Singh et al,
Journal of Drug Development & Research.
2011; 3(3), 70-84.
[15] Hanumanaik M, Patil Kumar, Patel SK, Singh
I, Jadatkar K, Design, Evaluation and Recent
Trends in Transdermal Drug Delivery System:
A Review, International Journal of
pharmaceutical sciences and research. 2012;
3(8),2393- 2406.

[16] Hock Tan S, William R, Pfister. Pressure-
sensitive adhesives for transdermal drug
delivery systems. PSTT. 1999; 2: 60-69.
[17] Gaikwad A, Transdermal drug deliverysystem:
Formulation Aspect and Evaluation.
Comprehensive Journal of Pharmaceutical
Sciences. 2013; Vol. 1(1) ,pp. 1 – 10
[18] Benson H, Transdermal drug delivery:
penetration enhancement techniques, Curr.
Drug Deliv. 2005; 2, 23–33.
[19] Rajesh M and Kishor D. A Review on
Transdermal Drug Delivery System. Research
J. Science and Tech. 2011; 3(5): 227-231.
[20] Kandavilli S, Nair V, Panchagnula R. Polymers
in transdermal drug delivery systems,
Pharmaceutical Technology 2002, 62-78.
Available from: www.pharmtech.com.
Accessed on 15 Jan,2008.
[21] Bang AK. Electrically Assisted Transdermal
and Topical Drug Delivery. Bristol, PA: Taylor
and Francis, Inc.;1998.
[22] Finnin BC, Morgan TM. Transdermal
penetration enhancers: applications, limitations,
and potential. J Pharm Sci. 1999:88(10):955-
958.
[23] Naik A, Kalia YN, Guy RH. Transdermal drug
delivery: overcoming the skin's barrier
function. PSTT. 2000:3(9):318- 326
[24] Baker RW, Heller J. Material selection for
transdermal delivery systems; In: Hadgraft J,
Guys RH, editors. Transdermal Drug Delivery:
Development Issues and Research Initiatives.
New York, Marcel Dekker Inc. 1989; 293-311.
[25] Kaza R, Pitchaimani R. Formulation of
transdermal drug delivery system: Matrix and
selection of polymer- their evaluation, Current
Drug Discovery Technologies 2006, 3, 279-
285.
[26] Parikh DK, Tapash KG. Feasibility of
transdermal delivery of fluoxetine, AAPS
PharmSciTech. 2005, 6, E144-149.
[27] Babu RJ, Pundit JK. Effect of permeation
enhancers on the transdermal delivery of
bupranolol through rat skin, Drug Delivery
2005, 12, 165-169.
[28] A Text book of Pharmaceutical Dosage forms
and Drug Delivery system by Howard C.Ansel,
Nicholas G.Popovich; page no. 357-359.
[29] Bhowmik D, Chiranjib,. Recent advances in
transdermal drug delivery system. Int. J Pharm
Tech Res. 2010; 2(1):68-77.
[30] Divya A, Rao MK, Gnanprakash K, Sowjanya
A, Vidyasagar N, Gobinath M. A review on
current scenario of transdermal drug delivery
system. Int. J Res. Pharm Sci. 2012;3(4):494-
502.
[31] Yadav V. Transdermal drug delivery system:
review. Int. J Pharm Sci. Res. 2012;3(2):376-
382.
[32] Ramteke KH, Dhole SN, Patil SV. Transdermal
drug delivery system: a review. J Advanced
Sci. Res. 2012; 3(1):22-35.
[33] Kumar D, Sharma N, Rana AC, Agarwal G,
Bhat ZA. A review: transdermal drug delivery
system: A tools for novel drug delivery sestem.
Int. J Drug Dev. Res. 2011; 3 (3):70-84.
[34] Joshi K, Selvaduary G. Transdermal drug
delivery system and their use of polymers.
MatE 175- Biomaterials. 1st 2008:1-28.
[35] Meidan V.Ultrasound-Enhanced Transdermal
Drug Delivery; Transdermal Drug
Delivery,Second Edition, Marcel Dekker Inc,
New York, USA; 2003.
[36] Langer R. Transdermal drug delivery: past
progress, current status and future prospects.
Advanced Drug Delivery Reviews 2004;
56:557 - 558.
[37] G. Agarwal, S. Dhawan. Development,
Fabrication and Evaluation of Transdermal
Drug Delivery System: A Review,
www.pharmainfo.net. 2009.
[38] Naik A, Kalia YN, Guy RH. Transdermal drug
delivery: Overcoming the skin’s barrier
function. PSTT. 3(9); 2009: 318-26.
[39] Wiechers J., "Use of chemical penetration
enhancers in transdermal drug delivery-
possibilities and difficulties", Acta Pharm,
1992, 4, 123.
[40] Srilatha M, Kottai M A. Transdermal drug
delivery system: A mini review. The Pharma
Innovation Journal 2019; 8(1): 181-197.
[41] Divyesh P, Nirav P, Meghal P, Navpreet K,
Transdermal drug delivery system: Review
International Journal of Biopharmaceutical and
Toxicology Research. 2011; 1(1):61-80.

Overview of Transdermal Drug Delivery System

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Overview of Transdermal Drug Delivery System

Similar to Overview of Transdermal Drug Delivery System (20)

More from ijtsrd

More from ijtsrd (20)

Recently uploaded

Recently uploaded (20)

Overview of Transdermal Drug Delivery System